Rocket Lab’s second quarter 2026 results, released today, August 10, 2026, painted a familiar picture for investors: robust top-line growth overshadowed by deepening bottom-line losses. The aerospace firm delivered a record $234.1 million in revenue, a notable 62% increase year-over-year and $34 million higher than Q1 2026's previous record, handily beating the consensus estimate of roughly $232.0 million. This strong performance, alongside a backlog soaring 137% year-over-year to $2.36 billion, unequivocally demonstrates surging demand for Rocket Lab’s launch services and space systems.
However, the enthusiasm was quickly tempered by the GAAP EPS of (0.06) by 33% and was even further below the whisper expectation of (0.03). The market reacted swiftly to this divergence, with [RKLB](https://www.kavout.com/stocks/nasdaq-rklb/rocket-lab-usa-inc) shares closing at \80.04 today, down 3.37% from yesterday’s close of $82.83. Beyond the immediate miss, the company's Q3 2026 gross margin guidance of 29–31% GAAP—significantly below the Q2 actual of 36.1% and prior Street expectations around 37.6%—introduced a fresh layer of concern. This guidance points to an ongoing, structural drag on profitability, compelling investors to question whether the current premium valuation can be sustained against the backdrop of an extended path to positive earnings and cash flow.
Rocket Lab's financials reveal a consistent pattern of strong revenue expansion juxtaposed with escalating operating expenses that prevent net profitability. Over the past five quarters, revenue climbed steadily from $144.5 million in Q2 2025 to today's reported $234.1 million for Q2 2026, marking a 62% year-over-year growth. Gross margins have shown resilience, hovering in the 36-38% range through Q1 2026 before today's lower guidance for Q3.
The challenge lies further down the income statement. While gross profit has grown, the absolute dollars spent on Research & Development (R&D) and Selling, General & Administrative (SG&A) have also swelled significantly. R&D expenses alone rose from $66.1 million in Q2 2025 to $82.4 million in Q2 2026, representing a 24.6% increase. This R&D spend has consistently consumed between 35-45% of quarterly revenue over the past year, reflecting heavy investment in the Neutron rocket and new space systems. Combined with SG&A, which jumped 49.6% year-over-year to $59.7 million in Q2 2026, total operating expenses now routinely exceed gross profit. For instance, in Q2 2026, the $84.6 million in gross profit was insufficient to cover the $142.1 million in combined R&D and SG&A, resulting in a GAAP operating loss of $(57.5) million. This incremental net loss on increased revenue suggests that, at its current cost structure, Rocket Lab's growth is not yet accretive to the bottom line.
| Metric (GAAP, $M) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | YoY Growth (Q2'25-Q2'26) |
|---|---|---|---|---|---|---|
| Revenue | 144.5 | 155.1 | 179.7 | 200.3 | 234.1 | +62.0% |
| Gross Margin | 32.0% | 37.0% | 38.0% | 38.2% | 36.1% | +4.1 pts |
| R&D | 66.1 | 70.7 | 78.8 | 80.5 | 82.4 | +24.6% |
| SG&A | 39.9 | 45.6 | 40.5 | 51.9 | 59.7 | +49.6% |
| Total Operating Ex | 106.0 | 116.3 | 119.3 | 132.5 | 142.1 | +34.1% |
| Operating Margin | -41.3% | -38.0% | -28.4% | -28.0% | -24.6% | +16.7 pts |
| Net Loss | (66.4) | (19.6) | (58.3) | (44.2) | (49.3) | -25.8% |
A significant factor contributing to the shifting profitability profile is Rocket Lab's evolving revenue mix. The company's Space Systems segment, encompassing satellite platforms, components, and mission services, is rapidly becoming the dominant revenue driver. In Q2 2026, Space Systems accounted for approximately 81% of total revenue at $181.3 million, while Launch Services represented a smaller 19% slice at $52.7 million. This marks a notable shift from Q4 2025, when Launch Services still made up 47.7% of revenue.
While Space Systems delivers substantial scale, it typically carries lower gross margins than the company’s launch business. In Q1 2026, Launch Services boasted a 44.3% gross margin, significantly higher than Space Systems' 35.3%. This mix shift, combined with the initial contributions from recent acquisitions like Mynaric, has a dilutive effect on consolidated margins. As CEO Peter Beck stated in the Q2 2026 press release, "We achieved a record $234 million in Q2 revenue... while continuing to invest in Neutron and expanding our Space Systems platform to serve a growing defense and commercial customer base."
CFO Adam Spice elaborated on the Q1 2026 earnings call, noting that "non-GAAP gross margin of 43% declined modestly from the fourth quarter as mix shifted toward Space Systems and SDA contributions at lower margins, while launch margin was slightly softer due to revenue mix." This trend has intensified into Q2, and the Q3 2026 gross margin guidance of 29–31% GAAP underscores that this lower-margin Space Systems work, especially on large-scale programs like SDA Tranches, is becoming a more substantial part of the current revenue mix.
At the heart of Rocket Lab's cost-of-growth narrative is the Neutron launch vehicle program. The development of this medium-lift rocket, including its Archimedes engines and reusable structures, is the primary driver behind the company's persistently high R&D spending. Neutron's significant investment needs are evident in the R&D figures, which have climbed from $174.4 million in fiscal year 2024 to $270.7 million in 2025, and reached $82.4 million in Q2 2026. This translates to R&D consuming over 35% of current revenue, far higher than what would be typical for a mature, profitable aerospace company.
Management has explicitly linked the turning point for profitability to Neutron's progress. As CFO Adam Spice stated on the Q2 2026 earnings call, "The turning point [to adjusted EBITDA positivity] will be the first successful test launch of Neutron; the quarter after that event happens will be where we see adjusted EBITDA positivity, and then about 18 to 24 months after that pivot to cash flow positivity." With the first Neutron launch now targeted for Q4 2026, this timeline pushes adjusted EBITDA positivity into early 2027 and free cash flow positivity into late 2028 or even 2029.
While Rocket Lab's balance sheet remains robust with $2.13 billion in cash and equivalents against minimal debt, the capital intensity of Neutron, including facilities, a recovery barge, and new production tooling, ensures that capital expenditures will remain elevated. This sustained investment, coupled with rising R&D, implies that the market is asked to underwrite a long and expensive journey before a meaningful return on the Neutron program materializes in the P&L.
Despite Rocket Lab's impressive revenue growth and backlog expansion, several risks suggest that its current valuation may be overly optimistic, particularly if the path to profitability deviates even slightly from current expectations.
First, the R&D and acquisition amortization drag on EPS is significant. Q2 2026 GAAP R&D of $82.4 million consumed 35.2% of revenue. CFO Adam Spice directly attributed the sequential EPS decline to the inclusion of Mynaric’s results and the amortization of acquired intangibles. With total Q2 2026 GAAP operating expenses at $142.1 million, exceeding gross profit by $57.5 million, the company consistently generates operating losses even with robust top-line growth. This implies that if R&D remains above 30% of revenue beyond the Neutron first flight, EBIT break-even will continue to slip beyond analyst models which project positive EPS of $0.92 by FY2030.
Second, the guided gross margin compression for Q3 2026 poses a direct threat to the premium valuation. The Q3 2026 guidance of 29–31% GAAP gross margin is a stark drop from Q2’s 36.1% and well below prior Street expectations of around 37.6%. This 6-8 percentage point reduction, driven by the mix shift to lower-margin Space Systems (e.g., SDA programs, Mynaric integration), suggests a fundamental re-rating of the company's margin profile is underway. Given the trailing twelve-month revenue of approximately $0.77 billion, an 8-point margin gap translates to a roughly $61.6 million annual gross profit shortfall.
Third, the valuation itself presents a substantial risk given the negative earnings. Rocket Lab trades at a trailing twelve-month (TTM) price-to-sales (P/S) ratio of 60.24x, compared to large defense peers at 1-3x. Its P/E and EV/EBITDA are deeply negative, at -289.06x and -281.93x respectively. While analysts project positive EPS by FY2029 ($0.57) and FY2030 ($0.92), these depend on aggressive revenue growth and a swift transition to margin expansion. If the profitability timeline slips by even 1-2 years, or if the multiple compresses towards a still-premium 20-30x sales for a high-growth specialist, the stock risks a 50%+ drawdown from current levels.
Finally, while Peter Beck's large July 2026 share sale (totaling ~$286.4 million via his family trust) was under a pre-arranged 10b5-1 plan, and CFO Adam Spice's earlier May 2026 sale was largely tax-driven, the optics of such significant insider selling at elevated prices while the company remains deeply unprofitable can undermine investor confidence. This behavior might be interpreted as insiders de-risking positions near peak valuations, regardless of the underlying mechanics.
Despite recent earnings disappointments, Wall Street analysts maintain a broadly bullish stance on Rocket Lab, albeit with a widening spread in their price targets. Out of 21 analysts covering RKLB, the consensus rating is a Buy, comprising 16 Buy ratings, 4 Holds, and 1 Sell. This aggregate view suggests a belief in Rocket Lab's long-term growth trajectory and market position.
However, the dispersion in price targets indicates growing caution and a lack of consensus on the timing and magnitude of profitability. The median analyst price target stands at $120.00, implying a substantial upside of approximately 49.9% from today's closing price of $80.04. The high target reaches $135.00, pointing to an even more optimistic 68.6% upside. In contrast, the low target is $83.00, which is just 3.7% above the current share price and effectively signals little to no near-term upside from at least one analyst.
This wide range, with the low target so close to the current price, reflects a clear division. While some analysts remain optimistic about the company's potential to eventually scale into its premium valuation, others are already factoring in the persistent cost of growth and margin pressures. The post-earnings dip and the current trading level, which sits below the lowest analyst target, suggest the market is leaning towards a more skeptical outlook than the consensus ratings imply.
The strongest objection to a thesis emphasizing persistent profitability drag is that Rocket Lab's adjusted EBITDA is much closer to break-even than GAAP EPS implies, and gross margins have shown structural improvements over the past year. In Q2 2026, the adjusted EBITDA loss was (20) million to (57.5) million, suggesting a large portion of the GAAP loss stems from non-cash items like stock-based compensation and acquisition-related amortization. Furthermore, Launch Services gross margins have consistently improved, reaching 44.3% in Q1 2026 from 11.2% in 2023, while Space Systems gross margins also expanded from 25.1% to 35.3% over the same period. This perspective argues that the underlying operational economics are improving, and the headline EPS misses are largely accounting artifacts or temporary investments.
However, this objection only partially holds up under scrutiny. While adjusted EBITDA shows progress, the scale of non-cash charges is too large to ignore for equity holders. Stock-based compensation in FY2025 totaled $71.1 million, representing about 11.8% of revenue. These are real costs to shareholders through dilution and are essential to retaining talent in a competitive industry. More critically, the recent Q3 2026 GAAP gross margin guidance of 29–31% represents a genuine decline in profitability, driven by a strategic mix shift towards lower-margin Space Systems programs and newly integrated acquisitions like Mynaric, rather than mere accounting noise. The problem isn't that launch margins are bad; it's that the overall revenue mix is diluting the consolidated gross margin, and operating expenses (including R&D) are scaling too quickly.
Therefore, while underlying operational improvements are visible in segments and adjusted EBITDA, Rocket Lab's profitability drag is not just an accounting issue. It is a fundamental challenge of scaling revenue through lower-margin businesses and absorbing heavy, ongoing R&D. The thesis narrows to acknowledge that the quality of growth in gross margin is improving in specific areas, but the mix of that growth, combined with aggressive investment in Neutron and acquisitions, creates genuine near-term margin compression. The figure that would decide it in the next report is a sustained GAAP gross margin above 33% and a deceleration in R&D as a percentage of revenue, demonstrating that the cost of growth is truly beginning to level off.
Rocket Lab (RKLB) remains a high-growth aerospace innovator with an expanding backlog and a pivotal role in the burgeoning space economy. However, the Q2 2026 earnings report and Q3 margin guidance confirm that its premium valuation has yet to fully account for the substantial and persistent costs of its ambitious growth strategy. The aggressive R&D spend on Neutron, combined with dilutive margin profiles from scaling Space Systems and acquisition integration, creates a longer and more challenging path to profitability than currently priced in.
Our stance is Neutral, with a preference for a lower entry point. While the long-term vision is compelling, the current share price of $80.04 (a 60.24x TTM P/S multiple) leaves little room for execution risk or further margin compression. We see a reasonable 12-month target of $105.00, representing a roughly 31% upside from today's price and reflecting a more conservative valuation multiple closer to 20-25x on FY2029 estimated sales. A more attractive entry zone would be in the low-$70s, where the stock traded prior to the recent earnings run-up, offering a better risk-reward proposition. This thesis would be invalidated if the stock closes below $68.00 for three consecutive days, signaling a break from recent support levels and a deeper market re-rating of its growth story. The ultimate success for RKLB hinges on Neutron delivering its promised high-margin cadence within the projected timeline, transforming the current cost-of-growth into sustained, profitable scale.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
